Stoke Therapeutics, Inc.
STOK · Nasdaq · United States
Share price · STOK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when STOK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Oct 2026-6.8%
- 24 Sep 2026-3.1%
Nothing announced by STOK that day or the session before.
- 23 Sep 2026-10.6%
Nothing announced by STOK that day or the session before.
- 4 Aug 2026+7.1%
- Day beforeOther material event
- 13 Jul 2026-6.1%
Nothing announced by STOK that day or the session before.
- 13 Mar 2026-9.0%
Nothing announced by STOK that day or the session before.
- 19 Feb 2026+10.9%
Nothing announced by STOK that day or the session before.
- 3 Feb 2026+9.8%
Nothing announced by STOK that day or the session before.
- 12 Jan 2026-10.4%
- 10 Dec 2025+12.1%
Nothing announced by STOK that day or the session before.
Share of unusual movement by asset
For each asset, the share of STOK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | SCN1A mRNARNA / oligonucleotide | Dravet Syndrome | |
| Preclinical / Unstaged | OPA1 (wild-type allele expression)RNA / oligonucleotide | Optic Neuropathy Autosomal Dominant Optic Atrophy |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $11M | $60M | $107M+ $212M short-term inv. | $74M-$63M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $9.3M | $50M | $110M+ $183M short-term inv. | $62M-$57M operating cash flow | report ↗ |
| 2026-Q1 | $6.2M | $40M | $156M+ $188M short-term inv. | $50M-$61M operating cash flow | report ↗ |
| 2025-Q3 | $11M | $38M | $83M+ $165M short-term inv. | $38M-$30M operating cash flow | report ↗ |
| 2025-Q2 | $14M | $26M | $101M+ $146M short-term inv. | $23M-$25M operating cash flow | report ↗ |
| 2025-Q1 | $159M | $33M | $275M+ $83M short-term inv. | —$132M operating cash flow | report ↗ |
| 2024-Q3 | $4.9M | $22M | $150M+ $89M short-term inv. | $26M-$22M operating cash flow | report ↗ |
| 2024-Q2 | $4.8M | $21M | $193M+ $89M short-term inv. | $26M-$17M operating cash flow | report ↗ |
| 2024-Q1 | $4.2M | $22M | $179M | $26M-$25M operating cash flow | report ↗ |
| 2023-Q3 | $3.3M | $20M | $190M+ $25M short-term inv. | $25M-$17M operating cash flow | report ↗ |
| 2023-Q2 | -$2.5M | $21M | $192M+ $39M short-term inv. | $31M-$22M operating cash flow | report ↗ |
| 2023-Q1 | $5.2M | $20M | $190M+ $63M short-term inv. | $23M-$21M operating cash flow | report ↗ |
| 2022-Q3 | $2.9M | $20M | $113M+ $138M short-term inv. | $26M-$22M operating cash flow | report ↗ |
| 2022-Q2 | $3.2M | $18M | $68M+ $208M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2022-Q1 | $3.0M | $18M | $84M+ $209M short-term inv. | $25M$32M operating cash flow | report ↗ |
| 2021-Q3 | — | $14M | $149M+ $87M short-term inv. | $23M-$15M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $184M | $138M | $84M+ $200M short-term inv. | $1.7M$46M operating cash flow | report ↗ |
Stoke Therapeutics reported FY 2025 revenue of $184.42M, up 404.4% YoY, with R&D spend of $137.92M, up 54.7% YoY. Cash and equivalents were $84.22M, while total cash, cash equivalents and marketable securities were approximately $391.7M as of December 31, 2025. The company reported a net loss of $6.88M and a quarterly net burn of $6.89M.
The company expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study in Q2 2026, with a data readout anticipated in mid-2027 and a rolling NDA submission planned to initiate in the first half of 2027. Discussions with the FDA are ongoing following a multidisciplinary meeting, and the company continues to explore expedited development and registration pathways for zorevunersen. Management is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company anticipates that its cash position, combined with eligible proceeds from the Biogen collaboration, will fund operations into 2028.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $37M | $89M | $128M+ $89M short-term inv. | $22M-$87M operating cash flow | report ↗ |
| 2023-FY | $8.8M | $82M | $191M+ $9.9M short-term inv. | $26M-$81M operating cash flow | report ↗ |
| 2022-FY | $12M | $78M | $114M+ $116M short-term inv. | $25M-$32M operating cash flow | report ↗ |
| 2021-FY | — | $54M | $145M+ $75M short-term inv. | $21M-$67M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 79 sales ($7.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Ticho Barry · CHIEF MEDICAL OFFICER | Open-market sale | 6,995 | $26.38 | $185K | Form 4 |
| 2026-11-02 | Ticho Barry · CHIEF MEDICAL OFFICER | Open-market sale | 200 | $26.99 | $5K | Form 4 |
| 2026-10-02 | Allan Jonathan · GENERAL COUNSEL & CORP SEC | Open-market sale | 627 | $26.33 | $17K | Form 4 |
| 2026-10-01 | Ticho Barry · CHIEF MEDICAL OFFICER | Open-market sale | 1,051 | $26.16 | $27K | Form 4 |
| 2026-09-23 | Cumbo Alexander · director | Award / grant (derivative) | 39,674 | — | — | Form 4 |
| 2026-09-01 | Ticho Barry · CHIEF MEDICAL OFFICER | Open-market sale | 3,945 | $30.51 | $120K | Form 4 |
| 2026-09-01 | Ticho Barry · CHIEF MEDICAL OFFICER | Open-market sale | 1,600 | $31.06 | $50K | Form 4 |
| 2026-08-18 | Allan Jonathan · GENERAL COUNSEL & CORP SEC | Open-market sale | 2,716 | $32.01 | $87K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 197 reporting institutions held 71.1M shares ($2.2B, 108.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 5,623,525 | $183.1M |
| 2 | BlackRock, Inc. | 5,385,714 | $175.4M |
| 3 | FMR LLC | 5,383,666 | $175.3M |
| 4 | Lynx1 Capital Management LP | 4,763,673 | $155.1M |
| 5 | Redmile Group, LLC | 4,164,120 | $135.6M |
| 6 | MORGAN STANLEY | 3,423,280 | $111.5M |
| 7 | BAKER BROS. ADVISORS LP | 3,336,697 | $108.6M |
| 8 | TORONTO DOMINION BANK | 3,173,258 | $103.3M |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 3,095,700 | $100.8M |
| 10 | BVF INC/IL | 2,547,557 | $82.9M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2,355,603 | $76.7M |
| 12 | STATE STREET CORP | 2,276,512 | $74.1M |
| 13 | Siren, L.L.C. | 1,995,347 | $65.0M |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1,823,500 | $59.4M |
| 15 | JANUS HENDERSON GROUP PLC | 1,612,781 | $52.5M |